In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.